Jennifer Kayden Lee - Feb 11, 2022 Form 4 Insider Report for RHYTHM PHARMACEUTICALS, INC. (RYTM)

Role: EVP, Head of North America
Signature: /s/ Hunter Smith, Attorney-in-Fact for Jennifer Chien
Stock symbol: RYTM
Transactions as of: Feb 11, 2022
Transactions value $: -$4,404
Form type: 4
Date filed: 2/15/2022, 06:28 PM
Previous filing: Feb 11, 2022
Next filing: Feb 3, 2023

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	RYTM	Common Stock	Options Exercise		+2.03K			2.03K	Feb 11, 2022	Direct	F1
transaction	RYTM	Common Stock	Sale	-$4.4K	-722	-35.53%	$6.10^*	1.31K	Feb 15, 2022	Direct	F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	RYTM	Restricted Stock Units	Options Exercise	$0	-2.03K	-25.01%	$0.00	6.09K	Feb 11, 2022	Common Stock	2.03K		Direct	F1, F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Each restricted stock unit represents a contingent right to receive one share of Issuer common stock.
F2	The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 instruction solely with the intent to cover withholding taxes in connection with the vesting of certain previously reported Restricted Share Units.
F3	The restricted stock units vest or have vested as to 25% of the total shares on each of February 11, 2022, February 11, 2023, February 11, 2024 and February 11, 2025. The restricted stock units have no expiration date.